Sugi Predict

Sugi Predict / Compounds / SCHEMBL289598

SCHEMBL289598

SCHEMBL289598

CC(C)c1ccc2c(c1)CC[C@H]1[C@@](C)(CNC[C@@]3(C)CCC[C@]4(C)c5ccc(C(C)C)cc5CC[C@@H]34)CCC[C@]21C

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.77
▸ CYP3A4 P08684 2/20 0.77
▸ KMT2A Q03164 2/20 0.77
▸ TSHR P16473 2/20 0.77
▸ KARS1 Q15046 1/20 0.77
▸ PDK1 Q15118 1/20 0.77
▸ PDK2 Q15119 1/20 0.77
▸ PDK3 Q15120 1/20 0.77
▸ PDK4 Q16654 1/20 0.77
▸ CYP2D6 P10635 1/20 0.77
▸ CYP2C9 P11712 1/20 0.77
▸ CYP2C19 P33261 1/20 0.77
▸ TP53 P04637 1/20 0.76
▸ MAPT P10636 1/20 0.76
▸ ALOX15 P16050 1/20 0.76
▸ MAPK1 P28482 1/20 0.76
▸ TDP1 Q9NUW8 10/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17470671 0.95 MEN1 (0.74) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL239240 0.95 MEN1 (0.74) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL29353573 0.95 MEN1 (0.74) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL19174219 0.95 MEN1 (0.74) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL18431217 0.92 TDP1 (0.76) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL14496633 0.92 TDP1 (0.76) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL16204336 0.91 MEN1 (0.74) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL18431216 0.91 MEN1 (0.74) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL9112389 0.90 TDP1 (0.68) MEN1CYP3A4KMT2ATSHRKARS1
SCHEMBL17459735 0.89 MEN1 (0.68) MEN1CYP3A4KMT2ATSHRKARS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4645671-A ANTIBIOTICS, ENZYME INHIBITORS BEECHAM GROUP P.L.C. (GB) 1987-02-24 — — US claimed
US-4584291-A ANTIBIOTICS AND BETA-LACTAMASE INHIBITORS BEECHAM GROUP P.L.C. (GB) 1986-04-22 — — US claimed
US-4544549-A ANTIBIOTICS, BETA-LACTAMASE INHIBITORS BEECHAM GROUP P.L.C. (GB) 1985-10-01 — — US claimed
US-11970480-B2 Heterocyclic amides useful as protein modulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-04-30 — — US disclosed
WO-2024073576-A1 4-((2-(3,5-DICHLOROPHENYL)-6-((PYRIMIDIN-5-YL)OXY)PYRIDIN-4-YL)METHYL)PIPERAZINE DERIVATIVES AS FURIN INHIBITORS AND USES THEREOF BP ASSET V, INC. (US) 2024-04-04 — — WO disclosed
US-11939343-B2 Sting agonist compounds and methods of use MERSANA THERAPEUTICS, INC. (US) 2024-03-26 — — US disclosed
EP-4313029-A1 COMBINATION THERAPY FOR CANCER TREATMENT The Regents of The University of Michigan (US) 2024-02-07 — — EP disclosed
WO-2023239892-A1 COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF ARKUDA THERAPEUTICS (US) 2023-12-14 — — WO disclosed
WO-2023237924-A1 DIHYDRAZIDE-DIHYDRAZONE COMPOUNDS WITH ADAMANTYL MOIETY AND A PROCESS FOR SYNTHESIS OF THE SAME PAWAR RUPA SACHIN (IN) 2023-12-14 — — WO disclosed
US-20230381159-A1 SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF UNIVERSITY OF MIAMI 2023-11-30 — — US disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
WO-1995003288-A1 HETEROAROMATIC DERIVATIVES AND THEIR USE IN THERAPEUTICS SMITHKLINE BEECHAM PLC (GB) 1995-02-02 — — WO disclosed
EP-0635007-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES SMITHKLINE BEECHAM PLC (GB) 1995-01-25 — — EP disclosed
WO-1993021166-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES SMITHKLINE BEECHAM PLC (GB) 1993-10-28 — — WO disclosed
EP-0295828-A1 Novel compounds BEECHAM GROUP PLC (GB) 1988-12-21 — — EP disclosed
US-4737492-A HYDRABAMINE AND BENZATHINE SALTS; SHELF LIFE ALCON LABORATORIES, INC. (US) 1988-04-12 — — US disclosed
US-4584291-A ANTIBIOTICS AND BETA-LACTAMASE INHIBITORS BEECHAM GROUP P.L.C. (GB) 1986-04-22 — — US disclosed
US-4544549-A ANTIBIOTICS, BETA-LACTAMASE INHIBITORS BEECHAM GROUP P.L.C. (GB) 1985-10-01 — — US disclosed
EP-0053893-B1 DERIVATIVES OF CLAVULANIC ACID, THEIR PREPARATION AND THEIR USE BEECHAM GROUP PLC (GB) 1985-03-20 — — EP disclosed
EP-0042232-A2 Cephalosporin derivatives, processes for their preparation and compositions containing them BEECHAM GROUP PLC (GB) 1981-12-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970480-B2 Heterocyclic amides useful as protein modulators RB1, RBBP5, RCC2 MEN1 2033/4885CYP3A4 4195/4885KMT2A 1428/4885
US-11939343-B2 Sting agonist compounds and methods of use STING1, IRF3, MAVS MEN1 4317/4885CYP3A4 4415/4885KMT2A 3969/4885
US-20230381159-A1 SMALL MOLECULE INHIBITORS OF CORONAVIRUS ATTACHMENT AND ENTRY, METHODS AND USES THEREOF ACE2, ACE, SARS1 MEN1 4001/4885CYP3A4 327/4885KMT2A 4436/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 MEN1 94/4885CYP3A4 2923/4885KMT2A 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback